Impact of metabolic syndrome on the outcomes of percutaneous renal angioplasty and stenting

(A) Survival: Kaplan-Meier analysis of survival of the patients with and without MetS. (B) Patency: Kaplan-Meier analysis of cumulative vessel patency with and without MetS. (C) Restenosis: Kaplan-Meier analysis of freedom from restenosis of the patients with and without MetS. (D) Hypertension: Kaplan-Meier analysis of freedom from recurrent hypertension of the patients with and without MetS. (E) Renal-related morbidity: Kaplan-Meier analysis of freedom from renal-related morbidity (persistent increase in creatinine >20% of baseline, progression to hemodialysis, death from renal-related causes) of the patients with and without MetS. The number at risk at each time interval is shown below each figure. Values are mean ± standard error of the mean. Standard errors exceeding 10% are not shown.